 |
PDBsum entry 1nqc
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase
|
 |
|
Title:
|
 |
Crystal structures of cathepsin s inhibitor complexes
|
|
Structure:
|
 |
Cathepsin s. Chain: a. Ec: 3.4.22.27
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606
|
|
Resolution:
|
 |
|
1.80Å
|
R-factor:
|
0.199
|
R-free:
|
0.219
|
|
|
Authors:
|
 |
T.A.Pauly,T.Sulea,M.Ammirati,J.Sivaraman,D.E.Danley,M.C.Griffor, A.V.Kamath,I.K.Wang,E.R.Laird,R.Menard,M.Cygler,V.L.Rath
|
Key ref:
|
 |
T.A.Pauly
et al.
(2003).
Specificity determinants of human cathepsin s revealed by crystal structures of complexes.
Biochemistry,
42,
3203-3213.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
21-Jan-03
|
Release date:
|
15-Apr-03
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P25774
(CATS_HUMAN) -
Cathepsin S from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
331 a.a.
217 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
*
PDB and UniProt seqs differ
at 1 residue position (black
cross)
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.4.22.27
- cathepsin S.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Similar to cathepsin L, but with much less activity on Z-Phe-Arg-|-NHMec, and more activity on the Z-Val-Val-Arg-|-Xaa compound.
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Biochemistry
42:3203-3213
(2003)
|
|
PubMed id:
|
|
|
|
|
| |
|
Specificity determinants of human cathepsin s revealed by crystal structures of complexes.
|
|
T.A.Pauly,
T.Sulea,
M.Ammirati,
J.Sivaraman,
D.E.Danley,
M.C.Griffor,
A.V.Kamath,
I.K.Wang,
E.R.Laird,
A.P.Seddon,
R.Ménard,
M.Cygler,
V.L.Rath.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Cathepsin S, a lysosomal cysteine protease of the papain superfamily, has been
implicated in the preparation of MHC class II alphabeta-heterodimers for antigen
presentation to CD4+ T lymphocytes and is considered a potential target for
autoimmune-disease therapy. Selective inhibition of this enzyme may be
therapeutically useful for attenuating the hyperimmune responses in a number of
disorders. We determined the three-dimensional crystal structures of human
cathepsin S in complex with potent covalent inhibitors, the aldehyde inhibitor
4-morpholinecarbonyl-Phe-(S-benzyl)Cys-Psi(CH=O), and the vinyl sulfone
irreversible inhibitor 4-morpholinecarbonyl-Leu-Hph-Psi(CH=CH-SO(2)-phenyl) at
resolutions of 1.8 and 2.0 A, respectively. In the structure of the cathepsin
S-aldehyde complex, the tetrahedral thiohemiacetal adduct favors the
S-configuration, in which the oxygen atom interacts with the imidazole group of
the active site His164 rather than with the oxyanion hole. The present
structures provide a detailed map of noncovalent intermolecular interactions
established in the substrate-binding subsites S3 to S1' of cathepsin S. In the
S2 pocket, which is the binding affinity hot spot of cathepsin S, the Phe211
side chain can assume two stable conformations that accommodate either the
P2-Leu or a bulkier P2-Phe side chain. This structural plasticity of the S2
pocket in cathepsin S explains the selective inhibition of cathepsin S over
cathepsin K afforded by inhibitors with the P2-Phe side chain. Comparison with
the structures of cathepsins K, V, and L allows delineation of local
intermolecular contacts that are unique to cathepsin S.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.Lee-Dutra,
D.K.Wiener,
and
S.Sun
(2011).
Cathepsin S inhibitors: 2004-2010.
|
| |
Expert Opin Ther Pat,
21,
311-337.
|
 |
|
|
|
|
 |
L.Mendieta,
A.Picó,
T.Tarragó,
M.Teixidó,
M.Castillo,
L.Rafecas,
A.Moyano,
and
E.Giralt
(2010).
Novel peptidyl aryl vinyl sulfones as highly potent and selective inhibitors of cathepsins L and B.
|
| |
ChemMedChem,
5,
1556-1567.
|
 |
|
|
|
|
 |
R.L.Cunha,
I.E.Gouvêa,
G.P.Feitosa,
M.F.Alves,
D.Brömme,
J.V.Comasseto,
I.L.Tersariol,
and
L.Juliano
(2009).
Irreversible inhibition of human cathepsins B, L, S and K by hypervalent tellurium compounds.
|
| |
Biol Chem,
390,
1205-1212.
|
 |
|
|
|
|
 |
S.J.Melton,
and
S.J.Landry
(2008).
Three dimensional structure directs T-cell epitope dominance associated with allergy.
|
| |
Clin Mol Allergy,
6,
9.
|
 |
|
|
|
|
 |
D.E.Danley
(2006).
Crystallization to obtain protein-ligand complexes for structure-aided drug design.
|
| |
Acta Crystallogr D Biol Crystallogr,
62,
569-575.
|
 |
|
|
|
|
 |
G.Kaulmann,
G.J.Palm,
K.Schilling,
R.Hilgenfeld,
and
B.Wiederanders
(2006).
The crystal structure of a Cys25 -> Ala mutant of human procathepsin S elucidates enzyme-prosequence interactions.
|
| |
Protein Sci,
15,
2619-2629.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.Linke,
R.E.Gordon,
M.Brillard,
F.Lecaille,
G.Lalmanach,
and
D.Brömme
(2006).
Degradation of apolipoprotein B-100 by lysosomal cysteine cathepsins.
|
| |
Biol Chem,
387,
1295-1303.
|
 |
|
|
|
|
 |
T.Rückrich,
J.Brandenburg,
A.Cansier,
M.Müller,
S.Stevanović,
K.Schilling,
B.Wiederanders,
A.Beck,
A.Melms,
M.Reich,
C.Driessen,
and
H.Kalbacher
(2006).
Specificity of human cathepsin S determined by processing of peptide substrates and MHC class II-associated invariant chain.
|
| |
Biol Chem,
387,
1503-1511.
|
 |
|
|
|
|
 |
L.Puzer,
S.S.Cotrin,
M.H.Cezari,
I.Y.Hirata,
M.A.Juliano,
I.Stefe,
D.Turk,
B.Turk,
L.Juliano,
and
A.K.Carmona
(2005).
Recombinant human cathepsin X is a carboxymonopeptidase only: a comparison with cathepsins B and L.
|
| |
Biol Chem,
386,
1191-1195.
|
 |
|
|
|
|
 |
K.M.Connolly,
B.T.Smith,
R.Pilpa,
U.Ilangovan,
M.E.Jung,
and
R.T.Clubb
(2003).
Sortase from Staphylococcus aureus does not contain a thiolate-imidazolium ion pair in its active site.
|
| |
J Biol Chem,
278,
34061-34065.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |